1. Home
  2. KRG vs RYTM Comparison

KRG vs RYTM Comparison

Compare KRG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kite Realty Group Trust

KRG

Kite Realty Group Trust

HOLD

Current Price

$24.63

Market Cap

5.0B

Sector

Real Estate

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$86.74

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRG
RYTM
Founded
1971
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.9B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
KRG
RYTM
Price
$24.63
$86.74
Analyst Decision
Buy
Strong Buy
Analyst Count
11
14
Target Price
$25.82
$131.14
AVG Volume (30 Days)
1.5M
985.0K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
4.70%
N/A
EPS Growth
6750.00
28.34
EPS
1.37
N/A
Revenue
$844,365,000.00
N/A
Revenue This Year
N/A
$55.17
Revenue Next Year
N/A
$95.98
P/E Ratio
$18.01
N/A
Revenue Growth
0.30
N/A
52 Week Low
$18.52
$49.86
52 Week High
$26.38
$122.20

Technical Indicators

Market Signals
Indicator
KRG
RYTM
Relative Strength Index (RSI) 45.34 48.03
Support Level $21.87 $84.39
Resistance Level $26.29 $97.19
Average True Range (ATR) 0.43 5.37
MACD -0.05 0.77
Stochastic Oscillator 32.34 48.67

Price Performance

Historical Comparison
KRG
RYTM

About KRG Kite Realty Group Trust

Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: